Hyperinsulinemic hypoglycemia: clinical, molecular and therapeutical novelties

Arianna Maiorana, Carlo Dionisi-Vici

Research output: Contribution to journalArticle

Abstract

Hyperinsulinemic hypoglycemia (HI) is the most common cause of hypoglycemia in children. Impairment of cellular pathways involved in insulin secretion from pancreatic β-cells, broadly classified as channelopathies and metabolopathies, have been discovered in the past two decades. The increasing use of NGS target panels, combined with clinical, biochemical and imaging findings allows differentiating the diagnostic management of children with focal forms, surgically curable, from those with diffuse forms, more conservatively treated with pharmacological and nutritional interventions. Specific approaches according to the subtype of HI have been established and novel therapies are currently under investigation. Despite diagnostic and therapeutic advances, HI remains an important cause of morbidity in children, still accounting for 26–44% of permanent intellectual disabilities, especially in neonatal-onset patients. Initial insult from recurrent hypoglycemia in early life greatly contributes to the poor outcomes. Therefore, patients need to be rapidly identified and treated aggressively, and require at follow-up a complex and regular monitoring, managed by a multidisciplinary HI team. This review gives an overview on the more recent diagnostic and therapeutic tools, on the novel drug and nutritional therapies, and on the long-term neurological outcomes.

Original languageEnglish
Pages (from-to)531-542
Number of pages12
JournalJournal of Inherited Metabolic Disease
Volume40
Issue number4
DOIs
Publication statusPublished - Jul 1 2017

Fingerprint

Hypoglycemia
Channelopathies
Intellectual Disability
Therapeutics
Pharmacology
Insulin
Morbidity
Drug Therapy

Keywords

  • Genetics
  • Hyperinsulinemic hypoglycemia
  • Hypoglycemia
  • Neurodevelopment
  • Novel therapies
  • Nutritional interventions

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Hyperinsulinemic hypoglycemia : clinical, molecular and therapeutical novelties. / Maiorana, Arianna; Dionisi-Vici, Carlo.

In: Journal of Inherited Metabolic Disease, Vol. 40, No. 4, 01.07.2017, p. 531-542.

Research output: Contribution to journalArticle

@article{7bbdf9fd2a19499da61582c2eaa5d204,
title = "Hyperinsulinemic hypoglycemia: clinical, molecular and therapeutical novelties",
abstract = "Hyperinsulinemic hypoglycemia (HI) is the most common cause of hypoglycemia in children. Impairment of cellular pathways involved in insulin secretion from pancreatic β-cells, broadly classified as channelopathies and metabolopathies, have been discovered in the past two decades. The increasing use of NGS target panels, combined with clinical, biochemical and imaging findings allows differentiating the diagnostic management of children with focal forms, surgically curable, from those with diffuse forms, more conservatively treated with pharmacological and nutritional interventions. Specific approaches according to the subtype of HI have been established and novel therapies are currently under investigation. Despite diagnostic and therapeutic advances, HI remains an important cause of morbidity in children, still accounting for 26–44{\%} of permanent intellectual disabilities, especially in neonatal-onset patients. Initial insult from recurrent hypoglycemia in early life greatly contributes to the poor outcomes. Therefore, patients need to be rapidly identified and treated aggressively, and require at follow-up a complex and regular monitoring, managed by a multidisciplinary HI team. This review gives an overview on the more recent diagnostic and therapeutic tools, on the novel drug and nutritional therapies, and on the long-term neurological outcomes.",
keywords = "Genetics, Hyperinsulinemic hypoglycemia, Hypoglycemia, Neurodevelopment, Novel therapies, Nutritional interventions",
author = "Arianna Maiorana and Carlo Dionisi-Vici",
year = "2017",
month = "7",
day = "1",
doi = "10.1007/s10545-017-0059-x",
language = "English",
volume = "40",
pages = "531--542",
journal = "Journal of Inherited Metabolic Disease",
issn = "0141-8955",
publisher = "Springer Netherlands",
number = "4",

}

TY - JOUR

T1 - Hyperinsulinemic hypoglycemia

T2 - clinical, molecular and therapeutical novelties

AU - Maiorana, Arianna

AU - Dionisi-Vici, Carlo

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Hyperinsulinemic hypoglycemia (HI) is the most common cause of hypoglycemia in children. Impairment of cellular pathways involved in insulin secretion from pancreatic β-cells, broadly classified as channelopathies and metabolopathies, have been discovered in the past two decades. The increasing use of NGS target panels, combined with clinical, biochemical and imaging findings allows differentiating the diagnostic management of children with focal forms, surgically curable, from those with diffuse forms, more conservatively treated with pharmacological and nutritional interventions. Specific approaches according to the subtype of HI have been established and novel therapies are currently under investigation. Despite diagnostic and therapeutic advances, HI remains an important cause of morbidity in children, still accounting for 26–44% of permanent intellectual disabilities, especially in neonatal-onset patients. Initial insult from recurrent hypoglycemia in early life greatly contributes to the poor outcomes. Therefore, patients need to be rapidly identified and treated aggressively, and require at follow-up a complex and regular monitoring, managed by a multidisciplinary HI team. This review gives an overview on the more recent diagnostic and therapeutic tools, on the novel drug and nutritional therapies, and on the long-term neurological outcomes.

AB - Hyperinsulinemic hypoglycemia (HI) is the most common cause of hypoglycemia in children. Impairment of cellular pathways involved in insulin secretion from pancreatic β-cells, broadly classified as channelopathies and metabolopathies, have been discovered in the past two decades. The increasing use of NGS target panels, combined with clinical, biochemical and imaging findings allows differentiating the diagnostic management of children with focal forms, surgically curable, from those with diffuse forms, more conservatively treated with pharmacological and nutritional interventions. Specific approaches according to the subtype of HI have been established and novel therapies are currently under investigation. Despite diagnostic and therapeutic advances, HI remains an important cause of morbidity in children, still accounting for 26–44% of permanent intellectual disabilities, especially in neonatal-onset patients. Initial insult from recurrent hypoglycemia in early life greatly contributes to the poor outcomes. Therefore, patients need to be rapidly identified and treated aggressively, and require at follow-up a complex and regular monitoring, managed by a multidisciplinary HI team. This review gives an overview on the more recent diagnostic and therapeutic tools, on the novel drug and nutritional therapies, and on the long-term neurological outcomes.

KW - Genetics

KW - Hyperinsulinemic hypoglycemia

KW - Hypoglycemia

KW - Neurodevelopment

KW - Novel therapies

KW - Nutritional interventions

UR - http://www.scopus.com/inward/record.url?scp=85021264021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021264021&partnerID=8YFLogxK

U2 - 10.1007/s10545-017-0059-x

DO - 10.1007/s10545-017-0059-x

M3 - Article

AN - SCOPUS:85021264021

VL - 40

SP - 531

EP - 542

JO - Journal of Inherited Metabolic Disease

JF - Journal of Inherited Metabolic Disease

SN - 0141-8955

IS - 4

ER -